+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Intravenous Iron Drugs Market Size, Share, & Trends Analysis Report by Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), Application (Chronic Kidney Disease), and Region with Growth Forecasts, 2025-2030- Product Image
Intravenous Iron Drugs Market Size, Share, & Trends Analysis Report by Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), Application (Chronic Kidney Disease), and Region with Growth Forecasts, 2025-2030- Product Image
New

Intravenous Iron Drugs Market Size, Share, & Trends Analysis Report by Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), Application (Chronic Kidney Disease), and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 150 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 5415624
Description Jump to:
The Intravenous Iron Drugs Market was valued at USD 3.32 billion in 2024, and is projected to reach USD 5.62 billion by 2030, rising at a CAGR of 9.10%. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights

  • Ferric carboxymaltose dominated the intravenous iron drugs industry in 2024 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost.
  • Iron sucrose held a significant share of the market in 2024. A low rate of severe allergic reactions has increased the adoption rate of these drugs.
  • The chronic kidney disease segment held the largest share in 2024, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases.
  • North America held the largest regional share in 2024 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD.
  • Asia-Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Intravenous Iron Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Intravenous Iron Drugs Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Iron Dextran
4.4.1. Iron Dextran Market, 2018-2030 (USD Million)
4.5. Iron Sucrose
4.5.1. Iron Sucrose Market, 2018-2030 (USD Million)
4.6. Ferric Carboxymaltose
4.6.1. Ferric Carboxymaltose Market, 2018-2030 (USD Million)
4.7. Others
4.7.1. Others Market, 2018-2030 (USD Million)
Chapter 5. Intravenous Iron Drugs Market: Application Business Analysis
5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Chronic Kidney Disease
5.4.1. Chronic Kidney Diseases Market, 2018-2030 (USD Million)
5.5. Inflammatory Bowel Disease
5.5.1. Inflammatory Bowel Disease Market, 2018-2030 (USD Million)
5.6. Cancer
5.6.1. Cancer Market, 2018-2030 (USD Million)
5.7. Other Diseases
5.7.1. Other Diseases Market, 2018-2030 (USD Million)
Chapter 6. Intravenous Iron Drugs Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
6.4. North America
6.4.1. North America Intravenous Iron Drugs Market Estimates And Forecasts, By Country, 2018-2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Europe
6.5.1. Europe Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. UK Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2017-2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. AbbVie Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. AMAG Pharmaceuticals (Covis Pharma)
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Daiichi Sankyo Company, Ltd.
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Sanofi
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Vifor Pharma Management Ltd. (CSL)
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. PHARMACOSMOS A/S
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Zydus Group
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Rockwell Medical, Inc.
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global intravenous iron drugs market, by region, 2018-2030 (USD Million)
Table 4 Global intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 5 Global intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 6 North America intravenous iron drugs market, by country, 2018-2030 (USD Million)
Table 7 North America intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 8 North America intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 9 U.S. intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 10 U.S. intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 11 Canada intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 12 Canada intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 13 Mexico intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 14 Mexico intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 15 Europe intravenous iron drugs market, by country, 2018-2030 (USD Million)
Table 16 Europe intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 17 Europe intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 18 UK intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 19 UK intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 20 Germany intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 21 Germany intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 22 France intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 23 France intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 24 Italy intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 25 Italy intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 26 Spain intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 27 Spain intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 28 Norway intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 29 Norway intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 30 Denmark intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 31 Denmark intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 32 Sweden intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 33 Sweden intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 34 Asia Pacific intravenous iron drugs market, by country, 2018-2030 (USD Million)
Table 35 Asia Pacific intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 36 Asia Pacific intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 37 Japan intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 38 Japan intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 39 China intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 40 China intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 41 India intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 42 India intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 43 Australia intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 44 Australia intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 45 South Korea intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 46 South Korea intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 47 Thailand intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 48 Thailand intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 49 Latin America intravenous iron drugs market, by country, 2018-2030 (USD Million)
Table 50 Latin America intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 51 Latin America intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 52 Brazil intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 53 Brazil intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 54 Argentina intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 55 Argentina intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 56 Middle East & Africa Intravenous iron drugs market, by country, 2018-2030 (USD Million)
Table 57 Middle East & Africa intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 58 Middle East & Africa intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 59 South Africa intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 60 South Africa intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 61 Saudi Arabia intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 62 Saudi Arabia intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 63 UAE intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 64 UAE intravenous iron drugs market, by application, 2018-2030 (USD Million)
Table 65 Kuwait intravenous iron drugs market, by product, 2018-2030 (USD Million)
Table 66 Kuwait intravenous iron drugs market, by application, 2018-2030 (USD Million)
List of Figures
Figure 1 Intravenous iron drugs market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and application outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Intravenous iron drugs market dynamics
Figure 12 Intravenous iron drugs market: Porter’s five forces analysis
Figure 13 Intravenous iron drugs market: PESTLE analysis
Figure 14 Product market, 2018-2030 (USD Million)
Figure 15 Iron Dextran market, 2018-2030 (USD Million)
Figure 16 Iron Sucrose market, 2018-2030 (USD Million)
Figure 17 Ferric Carboxymaltose market, 2018-2030 (USD Million)
Figure 18 Others market, 2018-2030 (USD Million)
Figure 19 Application market, 2018-2030 (USD Million)
Figure 20 Chronic kidney disease market, 2018-2030 (USD Million)
Figure 21 Inflammatory bowel disease market, 2018-2030 (USD Million)
Figure 22 Cancer market, 2018-2030 (USD Million)
Figure 23 Other Diseases market, 2018-2030 (USD Million)
Figure 24 Intravenous iron drugs market revenue, by region
Figure 25 Regional marketplace: Key takeaways
Figure 26 North America intravenous iron drugs market, 2018-2030 (USD Million)
Figure 27 U.S. country dynamics
Figure 28 U.S. intravenous iron drugs market, 2018-2030 (USD Million)
Figure 29 Canada country dynamics
Figure 30 Canada intravenous iron drugs market, 2018-2030 (USD Million)
Figure 31 Mexico country dynamics
Figure 32 Mexico intravenous iron drugs market, 2018-2030 (USD Million)
Figure 33 Europe intravenous iron drugs market, 2018-2030 (USD Million)
Figure 34 UK country dynamics
Figure 35 UK intravenous iron drugs market, 2018-2030 (USD Million)
Figure 36 Germany country dynamics
Figure 37 Germany intravenous iron drugs market, 2018-2030 (USD Million)
Figure 38 France country dynamics
Figure 39 France intravenous iron drugs market, 2018-2030 (USD Million)
Figure 40 Italy country dynamics
Figure 41 Italy intravenous iron drugs market, 2018-2030 (USD Million)
Figure 42 Spain country dynamics
Figure 43 Spain intravenous iron drugs market, 2018-2030 (USD Million)
Figure 44 Norway country dynamics
Figure 45 Norway intravenous iron drugs market, 2018-2030 (USD Million)
Figure 46 Sweden country dynamics
Figure 47 Sweden intravenous iron drugs market, 2018-2030 (USD Million)
Figure 48 Denmark country dynamics
Figure 49 Denmark intravenous iron drugs market, 2018-2030 (USD Million)
Figure 50 Asia Pacific intravenous iron drugs market, 2018-2030 (USD Million)
Figure 51 Japan country dynamics
Figure 52 Japan intravenous iron drugs market, 2018-2030 (USD Million)
Figure 53 China country dynamics
Figure 54 China intravenous iron drugs market, 2018-2030 (USD Million)
Figure 55 India country dynamics
Figure 56 India intravenous iron drugs market, 2018-2030 (USD Million)
Figure 57 Australia country dynamics
Figure 58 Australia intravenous iron drugs market, 2018-2030 (USD Million)
Figure 59 South Korea country dynamics
Figure 60 South Korea intravenous iron drugs market, 2018-2030 (USD Million)
Figure 61 Thailand country dynamics
Figure 62 Thailand intravenous iron drugs market, 2018-2030 (USD Million)
Figure 63 Latin America intravenous iron drugs market, 2018-2030 (USD Million)
Figure 64 Brazil country dynamics
Figure 65 Brazil intravenous iron drugs market, 2018-2030 (USD Million)
Figure 66 Argentina country dynamics
Figure 67 Argentina intravenous iron drugs market, 2018-2030 (USD Million)
Figure 68 MEA intravenous iron drugs market, 2018-2030 (USD Million)
Figure 69 South Africa country dynamics
Figure 70 South Africa intravenous iron drugs market, 2018-2030 (USD Million)
Figure 71 Saudi Arabia country dynamics
Figure 72 Saudi Arabia intravenous iron drugs market, 2018-2030 (USD Million)
Figure 73 UAE country dynamics
Figure 74 UAE intravenous iron drugs market, 2018-2030 (USD Million)
Figure 75 Kuwait country dynamics
Figure 76 Kuwait intravenous iron drugs market, 2018-2030 (USD Million)
Figure 77 Company categorization
Figure 78 Company market position analysis
Figure 79 Strategic framework

Companies Mentioned

The major companies featured in this Intravenous Iron Drugs market report include:
  • AbbVie Inc.
  • AMAG Pharmaceuticals (Covis Pharma)
  • Daiichi Sankyo Company, Ltd.
  • Sanofi
  • Vifor Pharma Management Ltd. (CSL)
  • PHARMACOSMOS A/S
  • Zydus Group
  • Rockwell Medical, Inc.

Table Information

Report AttributeDetails
No. of Pages150
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.32 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.62 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Intravenous Iron Drugs Market by Drug Type, Indication, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030 - Product Image

Intravenous Iron Drugs Market by Drug Type, Indication, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Iron Drugs Market by Drug Type, Indication, Distribution Channel, End User, Formulation - Global Forecast to 2030 - Product Image

Iron Drugs Market by Drug Type, Indication, Distribution Channel, End User, Formulation - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Intravenous (IV) Iron Drugs - Global Strategic Business Report - Product Image

Intravenous (IV) Iron Drugs - Global Strategic Business Report

  • Report
  • 354 Pages
  • Global
From
Intravenous Infusion Pumps Market Size, Share & Trends Analysis Report by Product (Volumetric Infusion Pumps, Syringe Infusion Pumps), Disease Indication (Chemotherapy, Diabetes, Gastroenterology), and Region with Growth Forecasts, 2025-2030 - Product Image

Intravenous Infusion Pumps Market Size, Share & Trends Analysis Report by Product (Volumetric Infusion Pumps, Syringe Infusion Pumps), Disease Indication (Chemotherapy, Diabetes, Gastroenterology), and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Intravenous (IV) Solutions - Global Strategic Business Report - Product Image

Intravenous (IV) Solutions - Global Strategic Business Report

  • Report
  • 487 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.